Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451632 | 0.86 | TDO2 (0.47) | SMN1; SMN2NPC1RAB9ATSHRMAPK9 | |
| SCHEMBL3450545 | 0.86 | MAPK9 (0.45) | SMN1; SMN2NPC1RAB9ATSHRCSNK2A1 | |
| SCHEMBL3451601 | 0.85 | BTK (0.42) | SMN1; SMN2NPC1RAB9ATSHRMAPK9 | |
| SCHEMBL3450200 | 0.85 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9ATSHRMAPK9 | |
| SCHEMBL3451095 | 0.84 | MEN1 (0.49) | SMN1; SMN2NPC1RAB9ATSHRMAPK9 | |
| SCHEMBL3348458 | 0.83 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9AMAPK9MAPK10 | |
| SCHEMBL3449885 | 0.83 | TDO2 (0.46) | MAPK1SMN1; SMN2NPC1RAB9ATSHR | |
| SCHEMBL3350959 | 0.82 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9ATSHRMAPK9 | |
| SCHEMBL13348486 | 0.82 | CSNK2A1 (0.45) | SMN1; SMN2NPC1RAB9ATSHRCSNK2A1 | |
| SCHEMBL13310863 | 0.81 | NPC1 (0.49) | MAPK1SMN1; SMN2NPC1RAB9AMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | MAPK1 2905/4885SMN1; SMN2 3328/4885NPC1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.